What Sunshine Biopharma Inc. reported on April 9, 2026
The quarter ending June 30, 2026, against the same quarter a year earlier.
| Measure | 3 months toJun 30, 2026 | 3 months toJun 30, 2025 | Change |
|---|
| Total Revenue | $9.3M | $9.4M | -1.56% |
| Profit | -$1.6M | -$1.8M | +11.68% |
| Free Cash Flow | -$925K | -$1.4M | +35.47% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
Earnings calls
NewThe latest call
FetchingSunshine Biopharma Inc. reported on November 12, 2026. We are fetching the call transcript; its summary follows once the transcript is in.
What management said
“We are pleased with our accomplishments in 2025, as we remain committed to reaching profitability in the near future,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
How the share price reacted
Releases land before the open or after the close, so the window runs from the close before the report day to the close of the session after it — the reaction is inside it either way.
Close before
$210.00
Apr 8, 2026
Close after
$199.68
Apr 10, 2026
Move
-4.91%
493 shares traded, against a normal 193
What Sunshine Biopharma Inc. does
Sunshine Biopharma currently markets 71 generic prescription drugs in Canada, with 12 additional launches planned for the remainder of 2026. The Company is also advancing two proprietary drug development programs: · K1.1 mRNA, an mRNA-Lipid Nanoparticle therapeutic candidate targeting liver cancer. · PLpro protease inhibitor, a small-molecule antiviral candidate for SARS-related coronavirus infections. Additional information is available at www.sunshinebiopharma.com.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Sunshine Biopharma Inc.’s Item 2.02 8-K filed April 9, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.
